A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas

Trial Profile

A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Nivolumab (Primary) ; Varlilumab (Primary)
  • Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Lymphatoid granulomatosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2018 Planned End Date changed from 30 Nov 2019 to 31 Dec 2019.
    • 07 Feb 2018 Planned primary completion date changed from 30 Nov 2019 to 31 Dec 2019.
    • 07 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top